·综述·立体定向放疗在超中央型肺癌治疗中的应用进展*于旭耀①王煜雯②综述宋勇春①审校摘要立体定向放射治疗（stereotacticbodyradiationtherapy，SBRT）可实现不可手术超中央型肺癌（ultra-centrallungcancer，UCLC）患者的靶区高剂量照射并较好保护危及器官，是目前临床治疗的探索热点。接受SBRT治疗后UCLC患者可获得较好的局部控制率、中位生存时间和总生存率，但是由于UCLC紧邻或侵犯纵隔内重要脏器，SBRT治疗会常伴有一定的不良反应风险。本文就SBRT应用于UCLC患者的临床实践及研究进展进行综述。关键词超中央型肺癌立体定向体部放射治疗处方剂量危及器官不良反应doi:10.12354/j.issn.1000-8179.2023.20220930Advancesinstereotacticbodyradiationtherapyforultra-centrallungcancerXuyaoYu1,YuwenWang2,YongchunSong1Correspondenceto:YongchunSong;E-mail:sych1977@qq.com1DepartmentofRadiationOncology,TianjinMedicalUniversityCancerInstitute&Hospital,NationalClinicalResearchCenterforCan-cer,Tianjin'sClinicalResearchCenterforCancer,KeyLaboratoryofCancerPreventionandTherapy,Tianjin300060,China;2Depart-mentofRadiotherapy,AirportHospital,TianjinMedicalUniversityCancerInstitute&Hospital,Tianjin300060,ChinaThisworkwassupportedbytheChinaPostdoctoralFundProject(No.2019M661039),ScienceandTechnologyProjectofTianjinHealthCommission(No.TJWJ2021QN009)andCancerTransformationMedicineSeedFundProjectofTianjinMedicalUniversityCan-cerInstituteandHospital(No.1903)AbstractStereotacticbodyradiationtherapy(SBRT)canachievehigh-doseirradiationinthetargetareasofpatientswithultra-centrallungcancer(UCLC)whilealsoprotectingthesurroundingorgansatrisk.SBRTisthegoldstandardofclinicaltreatmentforpatientswithUCLC.SomeclinicalstudiesonSBRTforUCLCtreatmenthaveshownthatitcanobtainabetterlocalcontrolrate,mediansurvivaltime,andoverallsurvivalratethanotherknowntreatmentmethods.However,becauseUCLCtissuesareclosetoorgansatriskinthepatient'smediastinum,SBRTtreatmentisoftenaccompaniedbytoxicityandsideeffects.ThisarticlereviewstheprogressofresearchonSBRTforthetreatmentofpatientswithUCLC.Keywords:ultra-centrallungcancer(UCLC),stereotacticbodyradiationtherapy(SBRT)...
